In vivo evaluation of nanostructured lipid carrier systems (NLCs) in mice bearing prostate cancer tumours.
Mushfiq AkandaGiulia GettiDionysios DouroumisPublished in: Drug delivery and translational research (2021)
Nanostructure lipid carriers (NLCs) were developed for the delivery of curmumin (CRN), a potent anticancer agent with low bioavailability, for the treatment of prostate cancer. NLCs prepared using high pressure homogenization (HPH) with around 150 nm particle size, - 40 V ζ-potential and excellent long-term stability. Cellular uptake of CRN-SLN showed nanoparticle localization in the cytoplasm around the nucleus. CRN-NLCs were assessed using flow cytometry and found to cause early and late apoptotic events at 100 μg/ml CRN concentrations. CRN-NLC nanoparticles were administrated to nude mice with LNCaP prostate cancer xenografts and demonstrated substantial tumour volume suppression (40%) with no weight loss compared to pure CRN (ethanolic solution). Overall, NLCs were proved a suitable carrier for passive drug delivery and cancer treatment.
Keyphrases
- prostate cancer
- radical prostatectomy
- flow cytometry
- drug delivery
- weight loss
- high fat diet induced
- cell death
- bariatric surgery
- fatty acid
- type diabetes
- adipose tissue
- photodynamic therapy
- metabolic syndrome
- combination therapy
- risk assessment
- roux en y gastric bypass
- squamous cell carcinoma
- gastric bypass
- body mass index
- neoadjuvant chemotherapy